In particular, studying factors such as histologic type, death receptor status, biomarker status (e.g. MUC16 and mesothelin), specific tumor genotypes, early versus advanced stage disease, and upfront versus recurrent setting, we may better elucidate the role and impact TR3 might have as a therapeutic in ovarian cancer. This evidence concerns the gene MUC16 and ovarian carcinoma.